MSH6 and PMS2 expression in colorectal carcinoma
Safin M, Marylilly S, Janhavi MS
TL;DR
This study examines MSH6 and PMS2 protein levels in colorectal cancer to better understand their role in diagnosis and prognosis.
Contribution
The study identifies a 30% occurrence of combined MSH6 and PMS2 loss in CRC, linked to specific tumor characteristics.
Findings
Combined loss of MSH6 and PMS2 (MSI-H) was found in 30% of colorectal cancer cases.
MSI-H was more common in poorly differentiated and T3 stage tumors.
MSI-H was associated with stage II and III cancers and node-positive groups.
Abstract
Microsatellite instability (MSI) is a key feature in colorectal carcinomas (CRCs), but its role in diagnosis and prognosis, particularly through immunohistochemical markers like MSH6 and PMS2, remains underexplored. Conducted at Sree Balaji Medical College and Hospital, 50 histologically confirmed CRC samples were analyzed. Combined loss of MSH6 and PMS2 (MSI-H) was found in 30% of cases, particularly in poorly differentiated tumors, T3 stage tumors, stage II and III cancers, and node-positive groups. Thus, understanding of microsatellite instability (MSI) detection in colorectal carcinomas (CRCs) using immune histochemical markers MSH6 and PMS2, improving diagnostic and prognostic approaches for CRC.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsGenetic factors in colorectal cancer · Ferroptosis and cancer prognosis · Digestive system and related health